New hope for aggressive breast cancer: SKB264 faces off against chemo in major trial
NCT ID NCT06279364
First seen Jan 30, 2026 · Last updated Jun 10, 2026 · Updated 26 times
Summary
This study tests a new drug called SKB264 against standard chemotherapy as the first treatment for people with advanced triple-negative breast cancer that cannot be removed by surgery. The trial includes about 524 adults whose tumors do not have a certain protein (PD-L1) or who have already received immunotherapy for early-stage disease. The main goals are to see if SKB264 helps people live longer or keeps the cancer from growing longer than standard chemo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.